Journal Article10.1093/bja/56.11.1267
A protocol for the investigation of malignant hyperpyrexia (mh) susceptibility
378
TL;DR: A protocol for investigating malignant hyperpyrexia (MH) susceptibility has been established, allowing diagnoses of MHS, MHN and MHE.
read more
Abstract: A European Malignant Hyperpyrexia Group has been formed to facilitate exchange of information between centres performing in vitro muscle testing for malignant hyperpyrexia susceptibility. Data have been collected according to a protocol agreed by the Group. Based on these results, test criteria have been established to allow the following diagnoses to be made: MH susceptible (MHS); MH normal (MHN) or MH equivocal (MHE). It is accepted that MHE classified patients will be under permanent review, pending the collection of further data.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Ondansetron-induced muscular contractures in malignant hyperthermia-susceptible individuals.
TL;DR: Ondansetron induced contractures in skeletal muscle bundles in vitro and was significantly higher in MHS than in MHN muscle, suggesting that a trigger potency in vivo seems unlikely.
Malignant hyperthermia, a Scandinavian update
TL;DR: Malignant Hyperthermia is a rare pharmacogenetic disorder, triggered by halogenated anesthetics and/or succinylcholine and linked to mutations in the large ryanodine 1 gene (RYR1) gene in the majority of cases.
Congenital and Other Structural Myopathies
James J. Dowling,Kathryn N. North,Hans H. Goebel,Alan H. Beggs +3 more
- 01 Jan 2015
TL;DR: The congenital myopathies are a heterogeneous group of neuromuscular disorders defined by distinctive morphologic abnormalities of skeletal muscle with weakness and hypotonia, making genetic diagnosis a critical adjunct to traditional clinical and pathological evaluations.
The current status of malignant hyperthermia
TL;DR: The epidemiology, clinical symptoms, diagnosis and treatments of MH are summarized, and any new developments are summarized.
Malignant Hyperthermia in PICU—From Diagnosis to Treatment in the Light of Up-to-Date Knowledge
TL;DR: Malignant hyperthermia (MH) is a rare, hereditary, life-threatening disease triggered by volatile anesthetics and succinylcholine as mentioned in this paper , and it can occur after non-pharmacological triggers too.